Mutations in gyrA and gyrB among fluoroquinolone-and multidrug-resistant Mycobacterium tuberculosis isolates

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2090-2096

  Chien, Jung Yien ^a,b   Chiu, Wei Yih ^a,b   Chien, Shun Tien ^c   Chiang, Chia Jung ^c   Yu, Chong Jen ^b   Hsueh, Po Ren ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Chest Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT; CODON; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; EAST ASIAN; GENE MUTATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; ASIAN CONTINENTAL ANCESTRY GROUP; CAUCASIAN; DRUG EFFECTS; ENZYMOLOGY; ETHNOLOGY; EUROPE; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; TAIWAN; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CODON; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUOROQUINOLONES; GENE EXPRESSION; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PREVALENCE; TAIWAN; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

EID: 84963575858     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01049-15     Document Type: Article

References (24)

1. Gillespie SH, Billington O. 1999. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 44:393-395. http://dx.doi.org/10.1093/jac/44.3.393.
2. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 67:1088-1093. http://dx.doi.org/10.1093/jac/dks033.
3. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rusch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. 2011. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38:516-528. http://dx.doi.org/10.1183/09031936.00073611.
4. Centers for Disease Control and Prevention. 2006. Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 55:1176.
5. Lai CC, Tan CK, Huang YT, Chou CH, Hung CC, Yang PC, Luh KT, Hsueh PR. 2008. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. Clin Infect Dis 47:e57-e63. http://dx.doi.org/10.1086/591702.
6. Chernyaeva E, Fedorova E, Zhemkova G, Korneev Y, Kozlov A. 2013. Characterization of multiple and extensively drug resistant Mycobacterium tuberculosis isolates with different ofloxacin-resistance levels. Tuberculosis (Edinb) 93:291-295. http://dx.doi.org/10.1016/j.tube.2013.02.005.
7. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819-831. http://dx.doi.org/10.1093/jac/dkr566.
8. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC. 2007. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59:860-865. http://dx.doi.org/10.1093/jac/dkm061.
9. Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR. 2012. High proportion offluoroquinolone-resistantMycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol 50:1390-1396. http://dx.doi.org/10.1128/JCM.05286-11.
10. Murray PR, Baron EJ. 2007. Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
11. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard-2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35:907-914.
13. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, Bifani P, Kurepina N, Kreiswirth B, Sola C, Rastogi N, Vatin V, Gutierrez MC, Fauville M, Niemann S, Skuce R, Kremer K, Locht C, van Soolingen D. 2006. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 44:4498-4510. http://dx.doi.org/10.1128/JCM.01392-06.
14. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, Cole ST, Jacobs WR, Jr, Telenti A. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38:773-780. http://dx.doi.org/10.1128/AAC.38.4.773.
15. Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY, Moroz AM. 2013. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosisto levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol 62:108-113. http://dx.doi.org/10.1099/jmm.0.046821-0.
16. Yin X, Yu Z. 2010. Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. J Infect 61:150-154. http://dx.doi.org/10.1016/j.jinf.2010.05.001.
17. Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 12:7-11. http://dx.doi.org/10.1089/mdr.2006.12.7.
18. Matrat S, Veziris N, Mayer C, Jarlier V, Truffot-Pernot C, Camuset J, Bouvet E, Cambau E, Aubry A. 2006. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother 50:4170-4173. http://dx.doi.org/10.1128/AAC.00944-06.
19. Takiff HE, Cimino M, Musso MC, Weisbrod T, Martinez R, Delgado MB, Salazar L, Bloom BR, Jacobs WR, Jr. 1996. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci U S A 93:362-366. http://dx.doi.org/10.1073/pnas.93.1.362.
20. Hegde SS, Vetting MW, Roderick SL, Mitchenall LA, Maxwell A, Takiff HE, Blanchard JS. 2005. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 308:1480-1483. http://dx.doi.org/10.1126/science.1110699.
21. WHO. 2014. Companion handbook: to the WHO guidelines for the programmatic management of drug resistant tuberculosis. World Health Organization, Geneva, Switzerland.
22. Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. 2014. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother 58:364-369. http://dx.doi.org/10.1128/AAC.01228-13.
23. Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udwadia Z, Rodwell TC, Catanzaro A, Rodrigues C. 2015. Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRslassay. Tuberculosis (Edinb) 95:137-141. http://dx.doi.org/10.1016/j.tube.2014.11.003.
24. Li J, Gao X, Luo T, Wu J, Sun G, Liu Q, Jiang Y, Zhang Y, Mei J, Gao Q. 2014. Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. Emerg Microbes Infect 3:e19. http://dx.doi.org/10.1038/emi.2014.21.